Abstract
Purpose. To analyze the effect of various types of macular atrophy on the best corrected visual acuity (BCVA) and the central retinal zone thickness at the end of the first year of anti-VEGF therapy. Material and methods. The total number of patients included in the study was 219 (219 eyes). Results. The central zone thickness in the first group before treatment was 488.5 ± 178.2µm, in the second group – 455.9 ± 190.4µm; at the end of 1 year of treatment there was a decrease in both groups due to the edema resorption: 342.52 ± 114.62µm and 393.12 ± 113.28µm, respectively. Anti-VEGF therapy affects the resorption of macular edema, thereby preventing loss of visual acuity, but does not affect the development of macular atrophy. Conclusion. Due to anti-VEGF therapy, a BCVA increase is possible due to fluid resorption, but in patients with photoreceptor atrophy, visual acuity does not increase. Keywords: age-related macular degeneration, anti-VEGF therapy, retinal pigment epithelium, macular atrophy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
